Semnur

Semnur Pharmaceuticals, a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX) and Denali Capital Acquisition (NASDAQ:DECA), a special purpose acquisition company, on Tuesday entered into a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur up to $2B, with expected gross proceedsContinue Reading